# Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

> **NCT04448886** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ana C Garrido-Castro, MD** · enrollment: 110 (actual)

## Conditions studied

- Invasive Breast Cancer
- Metastatic Breast Cancer
- HR-Positive Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT04448886
- **Lead sponsor:** Ana C Garrido-Castro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-23
- **Primary completion:** 2024-03-09
- **Final completion:** 2027-06-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04448886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04448886, "Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04448886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*